GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant

Corporate Breaking News

Home : GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant

Feb 14 2018	GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant
YONGIN, South Korea, Feb. 13, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm")...


Source:https://www.prnewswire.com/news-releases/gc-pharma-and-lees-pharm-enter-into-china-licensing-agreement-to-develop-and-commercialise-gcc-4401c-an-investigational-anticoagulant-300598462.html

Related News
» Yoritex implemented exchange services for fiat and cryptocurrencies including VISA and MasterCard transactions as a part of the ongoing ICO campaign » Two Thirds of Middle East Bank CEOs at Risk of Losing Jobs According to Metin Mitchell Research